We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The controversial Patents (Amendment) Bill has passed in the Lok Sabha after
Commerce and Industry Minister Kamal Nath assured the Lower House that adequate
safeguards have been provided in the Bill to protect the interest of Indian
pharma industry and the poor people.
A Canadian court has ruled Canada's largest generic drug manufacturer can't
introduce a generic version of sanofi-aventis SA's blockbuster drug Plavix in
Canada.
GlaxoSmithKline exercised its option to license a third respiratory program
from Theravance, a decision that could be worth up to $252 million in upfront
and milestone payments to the South San Francisco biopharmaceutical.
Dutch biotechnology company Crucell N.V. and allied
contract manufacturer DSM Biologics announced that DSM Biologics has signed
a PER.C6 research license agreement with the Japanese pharmaceutical company
Mitsubishi Pharma Corporation.
Israel's cabinet has approved a significant boost to this year's
health spending, endorsing a proposal to increase the "basket" of
services provided under the National Health Insurance (NHI) scheme by NIS150mn
(US$34.62mn) in 2005.
A new survey in the key industrial region of São Paulo indicates
that Brazil's pharmaceutical sector continues to recover, outperforming the
overall rate of economic growth.
Leading research-based drugmakers with R&D operations in Spain
have called on the government to provide "selective assistance" for
the industry's drug development activities.
According to local studies, government moves in recent years to boost
Taiwan's biotechnology sector have led to a significant increase in sector revenue.
OSI Pharmaceuticals announced that the Swiss health authority, Swissmedic,
has approved Tarceva (erlotinib) for the treatment of patients with locally
advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at
least one prior chemotherapy regimen.